These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28254802)

  • 1. Genome Editing in Cardiovascular Biology.
    Seeger T; Porteus M; Wu JC
    Circ Res; 2017 Mar; 120(5):778-780. PubMed ID: 28254802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Progress in Genome Editing Approaches for Inherited Cardiovascular Diseases.
    Kaur B; Perea-Gil I; Karakikes I
    Curr Cardiol Rep; 2018 Jun; 20(7):58. PubMed ID: 29860642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9-mediated genome editing in human stem cell-derived cardiomyocytes: Applications for cardiovascular disease modelling and cardiotoxicity screening.
    Christidi E; Huang HM; Brunham LR
    Drug Discov Today Technol; 2018 Aug; 28():13-21. PubMed ID: 30205876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases.
    Chun YW; Durbin MD; Hong CC
    Curr Cardiol Rep; 2018 Apr; 20(6):38. PubMed ID: 29666931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future challenges for patient-specific induced pluripotent stem cells in cardiovascular medicine.
    Sun X; Tan G; Liew R
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):943-5. PubMed ID: 23030280
    [No Abstract]   [Full Text] [Related]  

  • 6. At the Heart of Genome Editing and Cardiovascular Diseases.
    Hernandez-Benitez R; Martinez-Martinez ML; Lajara J; Magistretti P; Montserrat N; Izpisua Belmonte JC
    Circ Res; 2018 Jul; 123(2):221-223. PubMed ID: 29976689
    [No Abstract]   [Full Text] [Related]  

  • 7. How genome editing could be used in the treatment of cardiovascular diseases.
    Musunuru K
    Per Med; 2018 Mar; 15(2):67-69. PubMed ID: 29714123
    [No Abstract]   [Full Text] [Related]  

  • 8. Paracrine Effects of the Pluripotent Stem Cell-Derived Cardiac Myocytes Salvage the Injured Myocardium.
    Tachibana A; Santoso MR; Mahmoudi M; Shukla P; Wang L; Bennett M; Goldstone AB; Wang M; Fukushi M; Ebert AD; Woo YJ; Rulifson E; Yang PC
    Circ Res; 2017 Sep; 121(6):e22-e36. PubMed ID: 28743804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Implications of CRISPR-Cas9 Genome Editing for IR.
    Perkons NR; Sheth R; Ackerman D; Chen J; Saleh K; Hunt SJ; Nadolski GJ; Shi J; Gade TP
    J Vasc Interv Radiol; 2018 Sep; 29(9):1264-1267.e1. PubMed ID: 30146193
    [No Abstract]   [Full Text] [Related]  

  • 11. The 3 pathways of translational medicine: an evolution to a call-and-response method.
    Fuster V
    J Am Coll Cardiol; 2014 Jul; 64(2):223-5. PubMed ID: 25011725
    [No Abstract]   [Full Text] [Related]  

  • 12. Pluripotent reprogramming and lineage reprogramming: promises and challenges in cardiovascular regeneration.
    He WJ; Hou Q; Han QW; Han WD; Fu XB
    Tissue Eng Part B Rev; 2014 Aug; 20(4):304-13. PubMed ID: 24063625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Annotation of TNNT2 Variants of Uncertain Significance With Genome-Edited Cardiomyocytes.
    Lv W; Qiao L; Petrenko N; Li W; Owens AT; McDermott-Roe C; Musunuru K
    Circulation; 2018 Dec; 138(24):2852-2854. PubMed ID: 30565988
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in induced pluripotent stem cells, genomics, biomarkers, and antiplatelet therapy highlights of the year in JCTR 2013.
    Barbato E; Lara-Pezzi E; Stolen C; Taylor A; Barton PJ; Bartunek J; Iaizzo P; Judge DP; Kirshenbaum L; Blaxall BC; Terzic A; Hall JL
    J Cardiovasc Transl Res; 2014 Jul; 7(5):518-25. PubMed ID: 24659088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome Editing: The Recent History and Perspective in Cardiovascular Diseases.
    Musunuru K
    J Am Coll Cardiol; 2017 Dec; 70(22):2808-2821. PubMed ID: 29191331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: CRISPR Medicine: From Bench to Bedside.
    Dellaire G
    Curr Gene Ther; 2017; 17(4):261-262. PubMed ID: 29361903
    [No Abstract]   [Full Text] [Related]  

  • 17. Induced pluripotent stem cells: at the heart of cardiovascular precision medicine.
    Chen IY; Matsa E; Wu JC
    Nat Rev Cardiol; 2016 Jun; 13(6):333-49. PubMed ID: 27009425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cells and their derivatives: a renaissance in cardiovascular translational research.
    Kattman SJ; Koonce CH; Swanson BJ; Anson BD
    J Cardiovasc Transl Res; 2011 Feb; 4(1):66-72. PubMed ID: 21061105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regenerative Medicine/Cardiac Cell Therapy: Pluripotent Stem Cells.
    Duran AG; Reidell O; Stachelscheid H; Klose K; Gossen M; Falk V; Röll W; Stamm C
    Thorac Cardiovasc Surg; 2018 Jan; 66(1):53-62. PubMed ID: 29216651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.